We protect your health through science
Investigation
Bacterial Genetics
Research projects
Content with Investigacion .
- Titulo: “Inmunidad entrenada en trasplante de órganos”.
Entidad financiadora. Ministerio de Ciencia, Innovación y Universidades
Referencia: Proyecto PID2019-110015RB-I00 financiado por MICIU/AEI/10.13039/501100011033
IP: Jordi Cano Ochando
Fechas de ejecución: 01/06/2020-31/05/2024
Presupuesto: 205.700 €
Publications
What’s in a name? Species-wide whole-genome sequencing resolves invasive and noninvasive lineages of Salmonella enterica serotype Paratyphi B
7. Connor, T.R., Owen, S.V., Langridge, G., Connell, S., Nair, S., Reuter, S., Dallman, T.J., Corander, J., Tabing, K.C., Le Hello, S., Fookes, M., Doublet, B., Zhou, Z., Feltwell, T., Ellington, M.J., Herrera, S., Gilmour, M., Cloeckaert, A., Achtman, M., Parkhill, J., Wain, J., De Pinna, E., Weill, F.-X., Peters, T., Thomson, N. What’s in a name? Species-wide whole-genome sequencing resolves invasive and noninvasive lineages of Salmonella enterica serotype Paratyphi B (2016) mBio, 7 (4).
PUBMED DOIInvasive salmonella infections among children from Rural Mozambique, 2001-2014
9. Mandomando, I., Bassat, Q., Sigaúque, B., Massora, S., Quintó, L., Ácacio, S., Nhampossa, T., Vubil, D., Garrine, M., Macete, E., Aide, P., Sacoor, C., Herrera-León, S., Ruiz, J., Tennant, S.M., Menéndez, C., Alonso, P.L. Invasive salmonella infections among children from Rural Mozambique, 2001-2014 (2015) Clinical Infectious Diseases, 61, pp. S339-S345.
PUBMED DOIFrecuencia de sustituciones relevantes asociadas a resistencia en la región NS5A a elbasvir en el virus de la hepatitis C en pacientes con genotipo 1a en España
2. Palladino C, Esteban-Cartelle B, Mate-Cano I, Sánchez-Carrillo M, Resino S, Briz V. Frecuencia de sustituciones relevantes asociadas a resistencia en la región NS5A a elbasvir en el virus de la hepatitis C en pacientes con genotipo 1a en España Enferm Infecc Microbiol Clin. 2018; 36 (5): 262-267. (A; FI= 1.707; Q2 Microbiology).
PUBMED DOIDevelopment of water-soluble polyanionic carbosilane dendrimers as novel and highly potent topical anti-HIV-2 microbicides.
4. Briz V, Sepulveda-Crespo D, Diniz AR; Borrego P, Rodes B; Javier de la Mata F, Gomez R, Taveira N, Muñoz-Fernandez MA. Development of water-soluble polyanionic carbosilane dendrimers as novel and highly potent topical anti-HIV-2 microbicides. Nanoscale 2015, 7(35): 14669-14683. (A; FI= 7.76; D1 Materials Science, Multidisciplinary).
PUBMED DOIHepatitis A outbreak disproportionately affecting men who have sex with men (MSM) in the European Union and European Economic Area, June 2016 to May 2017.
6. Hepatitis A outbreak disproportionately affecting men who have sex with men (MSM) in the European Union and European Economic Area, June 2016 to May 2017. Ndumbi P, Freidl GS, Williams CJ, Mårdh O, Varela C, Avellón A, …. Severi E; Members Of The European Hepatitis A Outbreak Investigation Team. Euro Surveill. 2018 Aug;23(33). doi: 10.2807/1560-7917.ES.2018.23.33.1700641.
PUBMED DOIDetection of hepatitis C virus (HCV) core-specific antibody suggests occult HCV infection among blood donors
7. Detection of hepatitis C virus (HCV) core-specific antibody suggests occult HCV infection among blood donors. Quiroga JA, Avellón A, Bartolomé J, Andréu M, Flores E, González MI, González R, Pérez S, Richart LA, Castillo I, Alcover J, Palacios R, Carreño V, Echevarría JM. Transfusion. 2016 Jul;56(7):1883-90. Epub 2016 May 17.
PUBMED DOIHepatitis E virus: Assessment of the epidemiological situation in humans in Europe, 2014/15.
8. Hepatitis E virus: Assessment of the epidemiological situation in humans in Europe, 2014/15. Adlhoch C, Avellon A, Baylis SA, Ciccaglione AR, Couturier E, de Sousa R, Epštein J, Ethelberg S, Faber M, Fehér Á, Ijaz S, Lange H, Manďáková Z, Mellou K, Mozalevskis A, Rimhanen-Finne R, Rizzi V, Said B, Sundqvist L, Thornton L, Tosti ME, van Pelt W, Aspinall E, Domanovic D, Severi E, Takkinen J, Dalton HR. J Clin Virol. 2016 Sep;82:9-16. Epub 2016 Jun 23.
PUBMED DOIFull coding hepatitis E virus genotype 3 genome amplification method
9. Full coding hepatitis E virus genotype 3 genome amplification method. Muñoz-Chimeno M, Forero JE, Echevarría JM, Muñoz-Bellido JL, Vázquez-López L, Morago L, García-Galera MC, Avellón A. J Virol Methods. 2016 Apr;230:18-23. Epub 2016 Jan 16.
PUBMED DOIAdditional Information
Streptococcus pneumoniae is a human pathogen that, despite the development of vaccines, continues to be an important cause of mortality and morbidity. We investigate the mechanisms of antibiotic resistance in this bacterium. On the one hand by identifying new therapeutic targets and on the other hand by investigating the molecular basis of the action of antibiotics already used in clinical practice (the fluoroquinolones levofloxacin and moxifloxacin) or not yet used (seconeolitsine). For this purpose, we used a multidisciplinary analysis involving genomics, transcriptomics and proteomics to understand the organization of the S. pneumoniae chromosome and the identification of the factors that stabilize this organization, including ncRNAs. Changes in the level of global supercoiling, either by inhibition of gyrase (decrease) or by inhibition of topoisomerase I (increase) alter the transcriptome. The modulated genes are located in domains, whose genes show specific functional characteristics. The aim is to identify new factors essential for S. pneumoniae physiology and to characterize transcriptional regulation in response to topological stress. In addition, RNA interference technology and CRISPR systems will be used as novel antibacterials. These studies will establish the bases for translational research aimed at the development of new therapeutic targets for the treatment of pneumococcal diseases.
Streptococcus pneumoniae is a human pathogen that, despite the development of vaccines, continues to be an important cause of mortality and morbidity. We investigate the mechanisms of antibiotic resistance in this bacterium. On the one hand by identifying new therapeutic targets and on the other hand by investigating the molecular basis of the action of antibiotics already used in clinical practice (the fluoroquinolones levofloxacin and moxifloxacin) or not yet used (seconeolitsine). For this purpose, we used a multidisciplinary analysis involving genomics, transcriptomics and proteomics to understand the organization of the S. pneumoniae chromosome and the identification of the factors that stabilize this organization, including ncRNAs. Changes in the level of global supercoiling, either by inhibition of gyrase (decrease) or by inhibition of topoisomerase I (increase) alter the transcriptome. The modulated genes are located in domains, whose genes show specific functional characteristics. The aim is to identify new factors essential for S. pneumoniae physiology and to characterize transcriptional regulation in response to topological stress. In addition, RNA interference technology and CRISPR systems will be used as novel antibacterials. These studies will establish the bases for translational research aimed at the development of new therapeutic targets for the treatment of pneumococcal diseases.